Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
- Sponsor
- Fuda Cancer Hospital, Guangzhou
- Study ID
- NCT04393220
- Phase
- PHASE2
- Status
- Completed
Conditions
- Progress Free Survival (PFS) and Overall Survival (OS)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab Injection — DRUG15mg/kg (Q3W)
- Nivolumab — DRUGnivolumab 480 mg IV infusions for 30 minutes q4w
Study Details
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
Key Dates
- Start date
- May 11, 2020
- Status verified
- Jun 2020
- Primary completion
- Jul 30, 2021
- Completion
- Aug 31, 2021
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Bevacizumab and anti-PD-1 therapy
- Active Comparator: Bevacizumab
- Active Comparator: anti-PD-1
Primary Outcome Measure
PFS [ Time Frame: 1.5 years ]